by Novo Nordisk
Eligible for BMI of 27* or 30 kg/m²*Check Eligibility
New: Wegovy is now also available as a daily tablet — in stock from £100/month. Prefer to skip the needles?
Explore the Wegovy Pill →Wegovy is an injectable prescription medicine used for chronic weight management in adults with obesity or overweight. It contains semaglutide, a GLP-1 receptor agonist that helps regulate appetite and calorie intake.
In clinical trials, Wegovy helped patients lose an average of 15% of their body weight when combined with lifestyle changes. The medication follows a carefully structured dose escalation schedule to help your body adjust and minimize side effects.
Wegovy is suitable for adults with a BMI of 30 or more, or 27 or more with at least one weight-related condition (such as high blood pressure, type 2 diabetes, or high cholesterol).
Wegovy is now available in a 7.2mg once-weekly high dose — three times the previous 2.4mg maximum. The MHRA approved the higher-dose regimen in January 2026 and the new single-dose 7.2mg pen on 14 April 2026; since June 2026 it comes as four single-use pens per month (one per weekly injection, disposed of after each use). We stock it now at our Timperley pharmacy, at a launch offer price of £250 per month including your monthly face-to-face pharmacist review.
In the 72-week STEP UP phase 3b trial (1,407 adults with obesity, across 11 countries), people taking semaglutide 7.2mg alongside diet and exercise lost an average of 20.7% of their body weight, compared with 17.5% on the standard 2.4mg dose. Notably, about one in three participants (33.2%) lost 25% or more — results in a range previously associated only with bariatric surgery or the highest dose of Mounjaro.
20.7%
average weight loss on 7.2mg over 72 weeks (STEP UP)
1 in 3
lost 25%+ of their body weight on the 7.2mg dose
£250
launch offer per month, monthly reviews included
The high dose is for adults with obesity (BMI 30 or above) who need more support than the standard 2.4mg maintenance dose — typically people whose weight loss has plateaued despite good adherence. It isn't a starting dose: you reach 7.2mg only after titrating up through the standard schedule and at least a month at 2.4mg, with each step confirmed at your face-to-face review. Side effects are the same gastrointestinal family as other doses and remain mostly mild to moderate, but they are more likely at higher doses — which is exactly why our in-person monthly monitoring matters.
WeightGone UK stocks the 7.2mg single-dose pens at our GPhC-registered pharmacy in Timperley, Altrincham — serving Sale, Hale, Stretford, Wythenshawe and the wider Greater Manchester area. The 7.2mg dose is not yet available on the NHS (a NICE assessment is expected to conclude towards late 2026), so private prescription is currently the only route. Already on 2.4mg with us or elsewhere? Book a review and we'll assess whether stepping up is right for you.
Wegovy treatment begins with a 4-week dose escalation period, starting at 0.25mg and stepping up the dose every 4 weeks before reaching the maintenance dose of 2.4mg weekly. This gradual increase helps minimize side effects.
Wegovy is a prescription-only medication. You'll need to complete a consultation with one of our healthcare professionals to determine if it's suitable for you.
Common questions about Wegovy (semaglutide) treatment at our Timperley pharmacy.
Wegovy (semaglutide) is a once-weekly injection that works on the GLP-1 hormone pathway to reduce appetite and help control how much you eat, supporting gradual weight loss alongside diet and lifestyle changes.
Results vary. In clinical trials, people lost an average of around 15% of their body weight over time when Wegovy was combined with lifestyle changes. Your pharmacist will give you realistic, personalised guidance.
Wegovy follows a structured dose-escalation schedule, starting low and increasing gradually to help your body adjust and limit side effects. Your pharmacist confirms each step at your monthly face-to-face review.
Common side effects include nausea, constipation or diarrhoea and reduced appetite, usually mild and easing over time. Gradual dose increases help, and your monthly review manages anything you experience.
Wegovy is available on the NHS for some people who meet stricter criteria, usually via specialist services with long waits. As a private pharmacy we can usually assess and, if suitable, start eligible patients within a few days.
Pricing depends on your dose and is shown on this page and confirmed at your consultation — from £100/month for the starting dose up to £225/month for 2.4 mg, with the new 7.2 mg high dose at a launch offer price of £250/month. There are no hidden fees, and your monthly face-to-face reviews are included.
Wegovy 7.2 mg is the new high dose of semaglutide — three times the previous 2.4 mg maximum — approved by the MHRA in 2026, with the single-dose 7.2 mg pen licensed on 14 April 2026. It comes as four single-use pens per month (one per weekly injection) and is stocked at our Timperley pharmacy.
In the 72-week STEP UP trial, adults taking 7.2 mg weekly alongside diet and exercise lost an average of 20.7% of their body weight (versus 17.5% on 2.4 mg), and about one in three lost 25% or more. Individual results vary — your pharmacist tracks yours at every monthly review.
7.2 mg is not a starting dose. You titrate through the standard schedule to 2.4 mg first, and if your progress has plateaued and you're tolerating treatment well, your pharmacist can step you up at a face-to-face review. If you're already on 2.4 mg elsewhere, book a review and we'll assess the step-up for you.
At WeightGone UK the 7.2 mg high dose is currently at a launch offer price of £250 per month, which includes four single-dose pens and your monthly face-to-face pharmacist review. It is not yet available on the NHS — a NICE assessment is expected to conclude towards late 2026.
WeightGone